A recent report published by the White House Council of Economic
Advisers ("CEA") on drug pricing in the
United States of America has put the cost of medicine and the
access thereto by the poor, firmly back in the spotlight, and on a
global scale.
In the CEA report, President Donald Trump's administration
argues that the USA pays higher prices for pharmaceuticals because
other developed countries have systems in place to actively force
down drug pricing. Some countries even force negative pricing on
pharmaceutical manufacturers meaning that certain drug prices are
adjusted downward each year, irrespective of increased input
costs.
The argument from the CEA, as we understand it, goes like this:
pharmaceutical companies charge high prices and achieve high
margins on sales to support the massively expensive research and
development activities to discover new drugs. The US, which has no
real form of universal healthcare, basically relies on free market
principles to